Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
Emergent BioSolutions entered a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million to support the process development and manufacturing of SAB-142 for type 1 diabetes. The contract leverages Emergent's Winnipeg facility for end-to-end services, including technology transfer and commercial manufacturing, contingent upon regulatory approval.
Key figures
- Deal Value Usd
- 50000000
- Contingent amount
- $36 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.